Coumadin (Warfarin): Who Still Needs It in the Age of Eliquis and Xarelto

If you’ve been prescribed Coumadin (warfarin) in 2026, you might be wondering why. You’ve probably heard about newer blood thinners like Eliquis (apixaban) and Xarelto (rivaroxaban), and maybe you’re wondering whether you should be on one of those instead. It’s a fair question. As a cardiologist, I prescribe DOACs far more often than warfarin these days, and for good reason. But warfarin hasn’t been retired, and there are specific patients in my practice who genuinely need it.

This guide walks through how warfarin works, why the newer medications have overtaken it for most people, and the important situations where warfarin remains the right choice.

How Warfarin Works

Warfarin is a vitamin K antagonist. Your liver needs vitamin K to produce four of the clotting factors (II, VII, IX, and X) that allow your blood to form clots. Warfarin blocks the enzyme (VKORC1) that recycles vitamin K back to its active form. With less active vitamin K available, your liver produces fewer functional clotting factors, and your blood’s ability to clot is reduced in a controlled way.

This mechanism is what makes warfarin both effective and demanding. Because it works through vitamin K, anything that changes your vitamin K levels (diet, antibiotics, illness, other medications) can shift warfarin’s potency. That’s why warfarin requires regular blood monitoring through the INR test, something the newer DOACs do not require.

Why DOACs Took Over

Between 2010 and 2015, four large clinical trials compared DOACs head-to-head against warfarin in patients with atrial fibrillation. All four showed their DOAC was at least as effective as warfarin for preventing strokes, and most demonstrated lower rates of intracranial bleeding. Combined with the practical advantages of fixed dosing, no dietary restrictions, and no regular blood tests, DOACs earned a Class I recommendation over warfarin in the 2019 AHA/ACC/HRS guidelines.

This shift made life easier for millions of patients and was a genuine advance in cardiovascular medicine. But it also created a misconception that warfarin is obsolete. It isn’t.

Five Situations Where Warfarin Is Still the Standard

1. Mechanical Heart Valves

This is the most absolute indication. The RE-ALIGN trial (2013, NEJM) tested dabigatran in patients with mechanical valves and was terminated early because patients on the DOAC had significantly more strokes, valve thrombosis, and bleeding than those on warfarin. The clotting that occurs on mechanical valve surfaces involves pathways that DOACs don’t adequately inhibit. If you have a mechanical valve, warfarin is the only proven oral anticoagulant, and you’ll take it for life with an INR target of 2.5 to 3.5.

2. Antiphospholipid Syndrome

Antiphospholipid syndrome (APS) is an autoimmune condition that causes abnormal blood clotting. For triple-positive APS patients (those with all three antiphospholipid antibody types), warfarin is clearly superior. The TRAPS trial was stopped early when rivaroxaban showed a higher rate of thrombotic events compared to warfarin. While emerging data suggests DOACs may be acceptable for certain lower-risk APS patients, warfarin remains the standard for arterial APS and triple-positive disease.

3. Rheumatic Mitral Stenosis

Patients with moderate-to-severe mitral stenosis from rheumatic heart disease who develop atrial fibrillation were excluded from every major DOAC trial. There is no randomized evidence for DOACs in this population. Warfarin is the only evidence-based anticoagulant option.

4. Severe Kidney Disease

All DOACs rely on the kidneys for clearance to varying degrees. Patients with creatinine clearance below 25-30 mL/min were excluded from the major DOAC trials. For advanced CKD and dialysis patients who need anticoagulation, warfarin is generally preferred because its metabolism doesn’t depend on renal function.

5. Left Ventricular Thrombus

After a large heart attack, blood clots can form inside the damaged left ventricle. Warfarin has the most robust evidence for dissolving these clots and preventing embolization. While some smaller studies have looked at DOACs for this indication, warfarin remains the preferred initial approach for most cardiologists.

INR Monitoring and Time in Therapeutic Range

If you’re on warfarin, your management revolves around the INR (International Normalized Ratio). The target for most patients is 2.0 to 3.0 (higher for mechanical valves). When your INR is below 2.0, you’re at increased risk for clots. When it’s above 3.0, you’re at increased risk for bleeding.

The quality of your warfarin management is measured by Time in Therapeutic Range (TTR), the percentage of time your INR stays in range. A TTR of 65% or higher is the benchmark for good control. Patients who consistently achieve this have outcomes that rival DOACs. Patients whose TTR falls below 60% may benefit from switching to a DOAC, a conversation worth having with your cardiologist.

Practical Tips for Warfarin Patients

Keep your vitamin K intake consistent. Don’t avoid leafy greens. They’re healthy. Just eat roughly the same amount each week so your dose stays calibrated.

Take it at the same time daily. Most patients take warfarin in the evening, which allows same-day dose adjustments after an INR check.

Tell every provider you’re on warfarin. The drug interaction list is extensive. Common culprits include antibiotics (especially metronidazole, fluconazole, trimethoprim-sulfamethoxazole), amiodarone, and NSAIDs.

Avoid NSAIDs when possible. Ibuprofen and naproxen significantly increase bleeding risk on warfarin. Acetaminophen (Tylenol) is a safer alternative for most people.

Carry identification. A medical alert bracelet or wallet card telling emergency providers you’re on an anticoagulant can change the course of your care in an emergency.

Warfarin Reversal: An Underappreciated Advantage

One area where warfarin has a practical edge is reversal. If you experience a life-threatening bleed or need emergency surgery, warfarin can be reversed quickly with intravenous vitamin K and four-factor prothrombin complex concentrate (4F-PCC). While DOACs now have reversal agents too (idarucizumab for dabigatran, andexanet alfa for the factor Xa inhibitors), warfarin reversal is more widely available and better established.

Should You Stay on Warfarin or Switch?

If you have a mechanical valve, APS, rheumatic mitral stenosis, or severe kidney disease, the answer is clear: stay on warfarin. For everyone else, the decision depends on how well your warfarin is managed. If your TTR is consistently below 65% and you’re struggling with dose adjustments, a DOAC may serve you better. But if you’ve been stable on warfarin for years with good control, there’s no mandate to switch. Well-managed warfarin works.

Anticoagulation Management in San Diego

Choosing the right blood thinner isn’t a one-size-fits-all decision. At my practice in Encinitas, I evaluate each patient’s medical history, kidney function, valve status, and practical circumstances to recommend the anticoagulant that offers the best balance of protection and safety. If you’re on warfarin and have questions, or if you need to start anticoagulation and want to understand your options, I’m happy to help. Contact us to schedule a consultation.

References

1. Eikelboom JW, et al. “Dabigatran versus Warfarin in Patients with Mechanical Heart Valves.” NEJM 369 (2013): 1206-1214.

2. Pengo V, et al. “Rivaroxaban vs Warfarin in High-Risk Patients with Antiphospholipid Syndrome (TRAPS).” Blood 132 (2018): 1365-1371.

3. Granger CB, et al. “Apixaban versus Warfarin in Patients with Atrial Fibrillation.” NEJM 365 (2011): 981-992.

4. Connolly SJ, et al. “Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RE-LY).” NEJM 361 (2009): 1139-1151.

5. Patel MR, et al. “Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation.” NEJM 365 (2011): 883-891.

6. January CT, et al. “2019 AHA/ACC/HRS Focused Update for the Management of Patients with Atrial Fibrillation.” Circulation 140 (2019): e125-e151.

7. Wan Y, et al. “Time in Therapeutic Range for Patients Taking Warfarin in Clinical Trials.” Circulation 118 (2008): 2029-2037.

8. Wadsworth D, et al. “A Review of Indications and Comorbidities in Which Warfarin May Be the Preferred Oral Anticoagulant.” Journal of Clinical Pharmacy and Therapeutics 46 (2021): 560-570.

Published on damianrasch.com. Written by Dr. Damian Rasch, D.O., board-certified invasive cardiologist. This content is for informational purposes only and does not constitute medical advice.